CHO cells are the predominant host for biotherapeutic protein expression with approximately 70% of licensed biologics manufactured in Chinese Hamster Ovary (CHO) cells. The ability to express therapeutic candidates in CHO cells early in the drug development process is advantageous as it minimizes changes in protein quality and function when transitioning to production scale. To address the lack of a robust and reproducible in-house transient CHO expression system, we incorporated the ExpiCHO™ transient expression system into our transient expression toolbox, joining the well-established HEK293-6E and Expi293™ systems. With an ever-expanding array of protein formats, the next challenge is being able to strategically match a construct with an expression system. We have utilized a diverse set of candidate proteins in an ongoing evaluation comparing material transiently produced in parallel in the HEK293-6E, ExpiCHO™ and Expi293™ systems for expression level and product quality. We report these results and discuss their implications in how we prioritize our selection of expression systems. Successful prioritization of an expression system for a drug modality will reduce parallel efforts and increase our throughput efficiency by reducing expression timelines
Biotechnology
Antibodies
Molecular Biology
Drug Discovery
Cancer Research
Gene Therapy
Cell Biology
Cancer Therapeutics
Clinical Research
Quality Control/assurance
Biochemistry
Pcr/rt-Pcr/real-Time Pcr
Systems Biology
Diabetes
Genetics
North America53%
Asia21%
South America18%
Europe3%
Africa3%
Website Visitors100%
Scientist21%
Research Scientist18%
Student14%
Executive7%
Educator/Faculty7%
Biologist7%
Lab Management7%
QC/QA4%
Genetic Counselor4%
Medical Doctor/Specialist4%
Medical Laboratory Technician4%
Facility/Department Manager4%
Biotech Company18%
Academic Institution9%
Clinical Laboratory9%
Private Practice3%
Industrial Company3%
Research Institute3%
Manufacturer & Biotech/pharma3%
Manufacturer - Other3%
Distribution/sales3%
Life Science Company3%